An Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) with Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy

Grants and Contracts Details

StatusFinished
Effective start/end date7/17/1212/31/15

Funding

  • Inc Research Inc: $95,471.00